Latest Biotech News

MIT researchers released BoltzGen, an update to their Boltz series that moves beyond structure prediction toward generalizable therapeutic design across modalities including nanobodies,...

MapLight Therapeutics priced a $250 million initial public offering to fund development of a small‑molecule rival to Bristol Myers Squibb’s schizophrenia treatment Cobenfy. The company said...

Intellia Therapeutics halted dosing and enrollment in two late-stage CRISPR gene‑editing trials after a participant was hospitalized with severe liver injury. The company stopped screening and...

Novartis agreed to acquire Avidity Biosciences for about $12 billion in cash, securing three late‑stage RNA‑based therapeutic programs for muscular dystrophies and related neuromuscular...

BridgeBio reported positive Phase 3 results for a rare‑disease candidate and is moving to adjust its regulatory strategy to pursue a U.S. filing. The interim analysis showed statistically...

Zenas Biopharma reported a 95% reduction in new gadolinium‑enhancing brain lesions at 12 weeks for obexelimab versus placebo in a Phase 2 trial for relapsing multiple sclerosis. The MoonStone...

Hemab Therapeutics raised $157 million in a financing round to advance a pipeline focused on underserved bleeding disorders. The funding, led by Sofinnova Partners and including Novo Holdings and...

Guardant Health and Zephyr AI announced a strategic partnership to combine Guardant’s multimodal molecular datasets with Zephyr’s AI analytics to accelerate discovery of genomic biomarkers for...

An MIT research team released BoltzGen, an open‑source generative model that moves from structural prediction toward generalizable therapeutic design across modalities including small molecules,...

MapLight Therapeutics filed for and priced a $250 million IPO to develop a competitor to Bristol Myers Squibb’s schizophrenia drug Cobenfy. The proceeds will finance clinical development of the...

Revvity reported third‑quarter results with 2% overall revenue growth to $698.9 million and a 3% rise in diagnostics revenue driven by newborn screening and immunodiagnostics. The company cited...

Flagship Pioneering-backed Expedition Medicines launched with an AI‑driven platform that analyzes proteome chemistry to design small molecules for targets considered undruggable. The company...

Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three late-stage RNA-based programs aimed at muscular dystrophies and related neuromuscular diseases. The Swiss...

Hemab Therapeutics closed a $157 million financing to advance a pipeline targeting underserved bleeding disorders, including two clinical-stage candidates. The round was led by Sofinnova Partners...

Novo Nordisk returned to the table and completed a roughly $4.7 billion acquisition of MASH drug developer Akero Therapeutics after earlier walking away from talks. The transaction consolidates...

Flagship Pioneering launched Expedition Medicines, an AI-driven startup that claims to learn chemistry rules to bind historically undruggable proteins. The company announced an R&D alliance with...

GSK struck a $357 million agreement with French biotech Syndivia to access a preclinical antibody-drug conjugate (ADC) program for prostate cancer. The deal covers preclinical work and potential...

Town Hall Ventures closed a $440 million fund to invest in startups using AI to expand healthcare access and outcomes for underserved populations. The firm targets companies that combine clinical...

Two studies highlight advances in infectious-disease surveillance: one used metagenomic sequencing to resolve strain-level pneumonia pathogens, and another linked rotavirus RNA trends in...

New computational tools advanced by two research teams promise to improve diagnostic classification and single-cell analysis workflows. A multi-institution validation showed AI models can classify...